About Lyell Immunopharma
Lyell Immunopharma is a company based in San Francisco (United States) founded in 2018 by Rick Klausner. Lyell Immunopharma has raised $493 million across 3 funding rounds from investors including GSK and Sahsen Ventures. The company has 300 employees as of December 31, 2024. Lyell Immunopharma has completed 1 acquisition, including ImmPACT-Bio. Lyell Immunopharma offers products and services including LYL314 and CAR T-cell Therapies. Lyell Immunopharma operates in a competitive market with competitors including Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Hummingbird Bioscience and Autolus, among others.
- Headquarter San Francisco, United States
- Employees 300 as on 31 Dec, 2024
- Founders Rick Klausner
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lyell Immunopharma, Inc.
-
Annual Revenue
$61 K (USD)-53.08as on Dec 31, 2024
-
Net Profit
-$342.99 M (USD)-46.18as on Dec 31, 2024
-
EBITDA
-$204.26 M (USD)11.38as on Dec 31, 2024
-
Total Equity Funding
$493 M (USD)
in 3 rounds
-
Latest Funding Round
$100 M (USD), Post-IPO
Jul 25, 2025
-
Investors
GSK
& 1 more
-
Employee Count
300
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Lyell Immunopharma
Lyell Immunopharma is a publicly listed company on the NASDAQ with ticker symbol LYEL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Lyell Immunopharma
Lyell Immunopharma offers a comprehensive portfolio of products and services, including LYL314 and CAR T-cell Therapies.
Targets relapsed large B-cell lymphoma through advanced cell therapies
Develops treatments for solid tumors and hematologic malignancies
People of Lyell Immunopharma
Unlock access to complete
Unlock access to complete
Funding Insights of Lyell Immunopharma
Lyell Immunopharma has successfully raised a total of $493M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $100 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Lyell Immunopharma
Lyell Immunopharma has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include GSK and Sahsen Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in multiple sectors are made by Sahsen Ventures.
|
Locked | Locked | Locked | |
|
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
Locked | Locked | Locked |
Investor details for Lyell Immunopharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lyell Immunopharma
Lyell Immunopharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ImmPACT-Bio.
Investment portfolio details for Lyell Immunopharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Biotechnology research and development are conducted in Israel.
|
Locked | Locked | 2017 | Locked |
Complete acquisition details for Lyell Immunopharma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Lyell Immunopharma
Detailed financials for Lyell Immunopharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lyell Immunopharma Comparisons
Peer comparison for Lyell Immunopharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lyell Immunopharma
Lyell Immunopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Hummingbird Bioscience and Autolus, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
Antibody drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases.
|
Detailed competitors of Lyell Immunopharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lyell Immunopharma
Complete news archive for Lyell Immunopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lyell Immunopharma
Lyell Immunopharma was founded in 2018.
Lyell Immunopharma is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Rick Klausner is the current CEO of Lyell Immunopharma. They have also founded this company.
Lyell Immunopharma is a funded company, having raised a total of $493M across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Lyell Immunopharma is 300.
Annual revenue of Lyell Immunopharma is $61K as on Dec 31, 2024.
Founded in 2018 and based in San Francisco, United States, the biotechnology firm focuses on oncology. CAR-T therapies are advanced for treating ROR1-positive non-small cell lung cancer and triple-negative breast cancer through the lead program LYL797. An autologous TIL therapy, LYL845, is pursued for multiple solid tumors. Operations center on clinical development of these immunotherapies to address unmet needs in cancer care.
Lyell Immunopharma's top competitors include Hummingbird Bioscience, Juno Therapeutics and Immatics.
Lyell Immunopharma offers LYL314 and CAR T-cell Therapies.
Yes, Lyell Immunopharma is publicly traded on NASDAQ under the ticker symbol LYEL.
Lyell Immunopharma has made 1 acquisition, including ImmPACT-Bio.
Lyell Immunopharma has 2 investors. Key investors include GSK, and Sahsen Ventures.
The ticker symbol of Lyell Immunopharma is LYEL on NASDAQ.